- £214.50bn
- £232.45bn
- $58.74bn
REG - AstraZeneca PLC - AstraZeneca to complete direct listing on NYSE
AnnouncementREG - AstraZeneca PLC - AZN new Head of Investor Relations Joris Silon
AnnouncementRCS - Redx Pharma Limited - US FDA lifts Partial Clinical Hold on Zelasudil
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Enhertu granted BTD for post-neoadjuvant early BC
AnnouncementREG - AstraZeneca PLC - Update on LATIFY Phase III trial of ceralasertib
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Subcutaneous Saphnelo approved in EU
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for 1L HER2+ metastatic BC
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for early gastric cancer
AnnouncementREG - AstraZeneca PLC - AstraZeneca manufacturing investment in Maryland
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the US
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement